A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

BACKGROUND: Copaxone is an efficacious and safe therapy that has demonstrated clinical benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On an individual level, patients show variability in their response to Copaxone, with some achieving significantly higher r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Genome Med
Autors principals: Ross, Colin J., Towfic, Fadi, Shankar, Jyoti, Laifenfeld, Daphna, Thoma, Mathis, Davis, Matthew, Weiner, Brian, Kusko, Rebecca, Zeskind, Ben, Knappertz, Volker, Grossman, Iris, Hayden, Michael R.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5450152/
https://ncbi.nlm.nih.gov/pubmed/28569182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-017-0436-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars